Danaher Corporation $DHR Stock: Danske Bank A S Increases Position

Danske Bank A S raised its holdings in shares of Danaher Corporation (NYSE:DHR) by 16.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 379,684 shares of the conglomerate’s stock after purchasing an additional 54,035 shares during the period. Danske Bank A S owned 0.05% of Danaher worth $84,119,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Danaher during the second quarter valued at approximately $10,492,520,000. Jupiter Topco LLC purchased a new stake in Danaher in the second quarter worth $1,456,317,000. Generation Investment Management LLP bought a new stake in Danaher in the second quarter valued at $1,287,949,000. Bank of America Corp DE bought a new stake in Danaher in the second quarter valued at $993,846,000. Finally, Legal & General Group Plc purchased a new position in Danaher during the 2nd quarter valued at $801,056,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.4%

DHR stock traded up $1.00 during midday trading on Friday, hitting $233.16. The stock had a trading volume of 3,359,470 shares, compared to its average volume of 4,152,061. The business has a 50-day moving average of $222.56 and a two-hundred day moving average of $201.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29. The firm has a market cap of $164.04 billion, a price-to-earnings ratio of 38.16, a price-to-earnings-growth ratio of 2.92 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating the consensus estimate of $1.92 by $0.19. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The business had revenue of $6.55 billion during the quarter, compared to analyst estimates of $6.56 billion. During the same quarter last year, the firm posted $1.89 earnings per share. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, equities research analysts forecast that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 26.19%.

Insider Activity

In other Danaher news, CAO Christopher Bouda sold 7,598 shares of the company’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total value of $1,782,186.88. Following the sale, the chief accounting officer owned 9,107 shares in the company, valued at approximately $2,136,137.92. This represents a 45.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gregory M. Milosevich sold 2,100 shares of the company’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $230.62, for a total transaction of $484,302.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $5,158,277.54. This trade represents a 8.58% decrease in their position. The SEC filing for this sale provides additional information. 10.80% of the stock is owned by company insiders.

Analyst Ratings Changes

DHR has been the subject of several research reports. Guggenheim upped their price objective on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. UBS Group reaffirmed a “buy” rating and set a $260.00 target price on shares of Danaher in a research note on Thursday, October 22nd. Royal Bank Of Canada boosted their price target on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday, October 5th. Citigroup boosted their price target on shares of Danaher from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Finally, Stifel Nicolaus increased their price target on shares of Danaher from $220.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $242.91.

About Danaher

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.